Top Ten most popular articles on Pharmafile.com this week

pharmafile | August 30, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharma, top 10 

Happy Friday! It’s time for another rundown of the top 10 most popular articles with Pharmafile.com readers this week.

10. NICE Chief Sir Andrew Dillon to step down in 2020

It’s the end of an era at NICE as its Chief Executive Sir Andrew Dillon announces that he will step down from his role at the end of March next year.

9. Oral contraceptive use as teenager linked to depression as an adult, study says

Women who have used oral contraceptives as teenagers are more likely to experience depression later in life, according to a study published in The Journal of Child Psychology and Psychiatry.

8. NICE refuses GW Pharma’s cannabis-based Epidyolex for treatment-resistant epilepsy

UK-based GW Pharma has suffered a setback in its home country after drug watchdog NICE chose not to recommend NHS reimbursement of Epidyolex (cannabidiol/CBD) in combination with clobazam for people with Dravet or Lennox-Gastaut syndrome (LGS), two forms of treatment-resistant epilepsy.

7. The Royal College of Obstetricians and Gynaecologists (RCOG) calls for action over shortages of hormone replacement therapy (HRT)

British healthcare leaders have called for a meeting with the government to discuss ongoing hormone replacement therapy (HRT) shortages.

6. Sacklers could give up Purdue Pharma and settle 2,000 lawsuits for $10-12 billion, proposal says

The Sackler family are offering to settle more than 2,000 opioid crisis lawsuits for between $10-12 billion, according to NBC.

5. FibroGen rocked by unexpected death of CEO Thomas B Neff

In a saddening turn of events, San Francisco-based FibroGen has announced that Thomas B Neff, its Chief Executive Officer and Chairman of the Board of Directors, unexpectedly passed away over the weekend.

4. Over half of all US/EU regulator warnings issued to Indian and Chinese manufacturers, report finds

Concerns have been raised concerning the integrity of the global supply chain after a report from The Pharmaceutical Journal revealed that over half of the total formal warnings issued by US and European regulatory bodies are directed at facilities based in India or China.

3. Johns Hopkins researchers to study psilocybin as a treatment for anorexia in Phase 1 trial

Scientists at Johns Hopkins University are exploring psilocybin as a potential treatment for chronic anorexia nervosa.

2. J&J must pay $572 million for fuelling opioid crisis in Oklahoma, judge says

A judge in Oklahoma has said that Johnson & Johnson must pay $572 million for the part it played in fuelling the opioid crisis which kills more than 130 a day in the United States.

1. Sea snail chemical could be used as preventative treatment for bowel cancer, study shows

A chemical produced by Australian sea snails is showing promise as a potential treatment for cancer, according to researchers from Australia.

Related Content

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

India report record number of COVID deaths as bodies drift down Ganges

India yesterday reported the country’s highest COVID-19 death total for a single day, with 4,205 …

Latest content